Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06298565 · ClinicalTrials.gov registry record
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
A clinical trial of Myasthenia Gravis, sponsored by argenx.
- Recruiting
- Registry status
- 680
- Enrollment target
- 20
- Study locations
NCT06298565: Recruiting study of Myasthenia Gravis, sponsored by argenx.
NCT06298565 is a study of Myasthenia Gravis that is actively recruiting participants, run by argenx. The registered enrollment target is 680 participants, above the 170-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (300% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06298565, a study of Myasthenia Gravis, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- 680 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Conditions Studied
Interventions
- BIOLOGICAL efgartigimod
Study Locations (20)
Florida
- SFM Clinical Research, LLC - Boca Raton
- University of Florida College of Medicine Jacksonville - Jacksonville Beach
- Medsol Clinical Research Center Inc - Port Charlotte
- BayCare Health System, Inc. St Anthony's Hospital - St. Petersburg
Other
- Kepler Universitätsklinikum, Universitätsklinik für Neurologie, Med Campus III - Linz
- UZ Leuven (University Hospitals Leuven) - Leuven
- Klinikum Altenburger Land GmbH - Altenburg
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Oregon
- Oregon Health and Science University - Portland
- University of Colorado Hospital - Portland
California
- UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center, - San Francisco
Illinois
- Prairie Education and Research Cooperative and HSHS Medical Group - O'Fallon
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2034-06 |
What NCT06298565 shows while recruiting
NCT06298565 is an observational study that tracks outcomes without assigning an intervention. The registered 680 participants enrollment target is mid-sized for trials with a published cap, above the 170-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (300% higher).
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which efgartigimod is the first listed.
NCT06298565 names 20 study sites across 13 states, led by Florida, Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06298565 about?
NCT06298565 is a clinical study titled "A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa". This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who...
What is the current status of trial NCT06298565?
This trial is currently recruiting. The enrollment target is 680 participants. The study started on 2024-11-04. Estimated completion is 2034-06.
What conditions does trial NCT06298565 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT06298565?
The interventions under investigation include: efgartigimod (BIOLOGICAL).
Who is sponsoring clinical trial NCT06298565?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06298565 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06298565's enrollment target sits among peer trials
680 3rd of 32 higher than 30 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RECRUITING
-
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI